Jiangxi Institute of Biological Products (HKSE:06915) Total Current Assets: HK$284.2 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:06915 Jiangxi Institute of Biological Products Inc HKSE:06915
23 GF Score
Price HK$16.72
! 3 Warning Signs
View Full Analysis

What is Jiangxi Institute of Biological Products Total Current Assets?

Jiangxi Institute of Biological Products HKSE:06915 +1.33% 23 Total Current Assets is HK$284.2 Mil as of Dec. 2025. GuruFocus rates HKSE:06915 with a GF Score™ of 23/100. The stock has 3 warning signs investors should review.

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Jiangxi Institute of Biological Products's total current assets for the quarter that ended in Dec. 2025 was HK$284.2 Mil.


Jiangxi Institute of Biological Products  (HKSE:06915) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Jiangxi Institute of Biological Products's Liquidation Value for the quarter that ended in Dec. 2025 is

Liquidation value
= Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=81.56-68.784+0.75 * 102.7+0.5 * 71.838
=125.7

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Jiangxi Institute of Biological Products Total Current Assets Related Terms


Jiangxi Institute of Biological Products Total Current Assets Historical Data

* Premium members only.

The historical data trend for Jiangxi Institute of Biological Products's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jiangxi Institute of Biological Products Total Current Assets Chart

Jiangxi Institute of Biological Products Annual Data
Trend Dec23 Dec24 Dec25
Total Current Assets
212.39 205.08 284.23

Jiangxi Institute of Biological Products Semi-Annual Data
Dec23 Dec24 Dec25
Total Current Assets 212.39 205.08 284.23
HKSE:06915
23GF Score
Jiangxi Institute of Biological Products Inc HKSE:06915
Total Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jiangxi Institute of Biological Products Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Jiangxi Institute of Biological Products's Total Current Assets for the fiscal year that ended in Dec. 2025 is calculated as

Jiangxi Institute of Biological Products's Total Current Assets for the quarter that ended in Dec. 2025 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Frequently Asked Questions Learn more about Total Current Assets →
What does a Total Current Assets of HK$284.2 Mil mean?
Jiangxi Institute of Biological Products (HKSE:06915) has a Total Current Assets of HK$284.2 Mil as of Dec. 2025. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Jiangxi Institute of Biological Products and its competitors.
Is Jiangxi Institute of Biological Products' Total Current Assets too high?
Jiangxi Institute of Biological Products' current Total Current Assets is HK$284.2 Mil. Overall, Jiangxi Institute of Biological Products has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Jiangxi Institute of Biological Products' Total Current Assets compare to LLY and JNJ?
Jiangxi Institute of Biological Products' Total Current Assets of HK$284.2 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Assets for a Drug Manufacturers company?
A good Total Current Assets depends on the Drug Manufacturers industry context. However, Total Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Assets mean?
A high Total Current Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Jiangxi Institute of Biological Products and its competitors. Jiangxi Institute of Biological Products's current Total Current Assets is HK$284.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangxi Institute of Biological Products stock overvalued right now?
Jiangxi Institute of Biological Products (HKSE:06915) has a current Total Current Assets of HK$284.2 Mil. The current Total Current Assets is HK$284.2 Mil. Jiangxi Institute of Biological Products' overall GF Score™ is 23/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Assets calculated?
Total Current Assets is calculated from a company's financial statements. For Jiangxi Institute of Biological Products (HKSE:06915), the current Total Current Assets is HK$284.2 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Jiangxi Institute of Biological Products Business Description

Address No. 198 Huoju Avenue, Jinggangshan Economic and Technological Development Zone, Jiangxi Province, Ji’an, CHN
Jiangxi Institute of Biological Products Inc is principally engaged in the business of research and development, and production and sale of human tetanus antitoxin. It operates as the provider and exporter of Human TAT in China and an antiserum platform company. Its products include biological products containing immunoglobulins or immunoglobulin F(ab')2 fragments, which are used in medical applications such as tetanus, snakebite envenoming, and rabies treatment. The majority of the company's revenue is derived from the sale of Human Tetanus Antitoxin in the Chinese mainland.
23GF Score

Get the complete analysis for HKSE:06915

Total Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$16.72
Price